Metabolomics identifies novel blood biomarkers of pulmonary function and copd in the general population

Bing Yu, Claudia Flexeder, Robert W. McGarrah, Annah Wyss, Alanna C. Morrison, Kari E. North, Eric Boerwinkle, Gabi Kastenmüller, Christian Gieger, Karsten Suhre, Stefan Karrasch, Annette Peters, Gregory R. Wagner, Gregory A. Michelotti, Robert P. Mohney, Holger Schulz, Stephanie J. London

Research output: Contribution to journalArticle

Abstract

Determination of metabolomic signatures of pulmonary function and chronic obstructive pulmonary disease (COPD) in the general population could aid in identification and understanding of early disease processes. Metabolome measurements were performed on serum from 4742 individuals (2354 African-Americans and 1529 European-Americans from the Atherosclerosis Risk in Communities study and 859 Europeans from the Cooperative Health Research in the Region of Augsburg study). We examined 368 metabolites in relation to cross-sectional measures of forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC), their ratio (FEV1/FVC) and COPD using multivariable regression followed by meta-analysis. At a false discovery rate of 0.05, 95 metabolites were associated with FEV1 and 100 with FVC (73 overlapping), including inverse associations with branched-chain amino acids and positive associations with glutamine. Ten metabolites were associated with FEV1/FVC and seventeen with COPD (393 cases). Enriched pathways of amino acid metabolism were identified. Associations with FEV1 and FVC were not driven by individuals with COPD. We identified novel metabolic signatures of pulmonary function and COPD in African and European ancestry populations. These may allow development of biomarkers in the general population of early disease pathogenesis, before pulmonary function has decreased to levels diagnostic for COPD.

Original languageEnglish
Article number61
JournalMetabolites
Volume9
Issue number4
DOIs
Publication statusPublished - 1 Apr 2019

Fingerprint

Pulmonary diseases
Metabolomics
Biomarkers
Chronic Obstructive Pulmonary Disease
Vital Capacity
Forced Expiratory Volume
Blood
Lung
Metabolites
Population
Branched Chain Amino Acids
Metabolome
Glutamine
Metabolism
African Americans
Meta-Analysis
Atherosclerosis
Health
Amino Acids
Serum

Keywords

  • Chronic obstructive pulmonary disease
  • Forced expiratory volume
  • Metabolome
  • Metabolomics
  • Respiratory function tests

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Molecular Biology

Cite this

Yu, B., Flexeder, C., McGarrah, R. W., Wyss, A., Morrison, A. C., North, K. E., ... London, S. J. (2019). Metabolomics identifies novel blood biomarkers of pulmonary function and copd in the general population. Metabolites, 9(4), [61]. https://doi.org/10.3390/metabo9040061

Metabolomics identifies novel blood biomarkers of pulmonary function and copd in the general population. / Yu, Bing; Flexeder, Claudia; McGarrah, Robert W.; Wyss, Annah; Morrison, Alanna C.; North, Kari E.; Boerwinkle, Eric; Kastenmüller, Gabi; Gieger, Christian; Suhre, Karsten; Karrasch, Stefan; Peters, Annette; Wagner, Gregory R.; Michelotti, Gregory A.; Mohney, Robert P.; Schulz, Holger; London, Stephanie J.

In: Metabolites, Vol. 9, No. 4, 61, 01.04.2019.

Research output: Contribution to journalArticle

Yu, B, Flexeder, C, McGarrah, RW, Wyss, A, Morrison, AC, North, KE, Boerwinkle, E, Kastenmüller, G, Gieger, C, Suhre, K, Karrasch, S, Peters, A, Wagner, GR, Michelotti, GA, Mohney, RP, Schulz, H & London, SJ 2019, 'Metabolomics identifies novel blood biomarkers of pulmonary function and copd in the general population', Metabolites, vol. 9, no. 4, 61. https://doi.org/10.3390/metabo9040061
Yu, Bing ; Flexeder, Claudia ; McGarrah, Robert W. ; Wyss, Annah ; Morrison, Alanna C. ; North, Kari E. ; Boerwinkle, Eric ; Kastenmüller, Gabi ; Gieger, Christian ; Suhre, Karsten ; Karrasch, Stefan ; Peters, Annette ; Wagner, Gregory R. ; Michelotti, Gregory A. ; Mohney, Robert P. ; Schulz, Holger ; London, Stephanie J. / Metabolomics identifies novel blood biomarkers of pulmonary function and copd in the general population. In: Metabolites. 2019 ; Vol. 9, No. 4.
@article{e1f23412ed6d4a669b4f2f9ccfeb3bb4,
title = "Metabolomics identifies novel blood biomarkers of pulmonary function and copd in the general population",
abstract = "Determination of metabolomic signatures of pulmonary function and chronic obstructive pulmonary disease (COPD) in the general population could aid in identification and understanding of early disease processes. Metabolome measurements were performed on serum from 4742 individuals (2354 African-Americans and 1529 European-Americans from the Atherosclerosis Risk in Communities study and 859 Europeans from the Cooperative Health Research in the Region of Augsburg study). We examined 368 metabolites in relation to cross-sectional measures of forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC), their ratio (FEV1/FVC) and COPD using multivariable regression followed by meta-analysis. At a false discovery rate of 0.05, 95 metabolites were associated with FEV1 and 100 with FVC (73 overlapping), including inverse associations with branched-chain amino acids and positive associations with glutamine. Ten metabolites were associated with FEV1/FVC and seventeen with COPD (393 cases). Enriched pathways of amino acid metabolism were identified. Associations with FEV1 and FVC were not driven by individuals with COPD. We identified novel metabolic signatures of pulmonary function and COPD in African and European ancestry populations. These may allow development of biomarkers in the general population of early disease pathogenesis, before pulmonary function has decreased to levels diagnostic for COPD.",
keywords = "Chronic obstructive pulmonary disease, Forced expiratory volume, Metabolome, Metabolomics, Respiratory function tests",
author = "Bing Yu and Claudia Flexeder and McGarrah, {Robert W.} and Annah Wyss and Morrison, {Alanna C.} and North, {Kari E.} and Eric Boerwinkle and Gabi Kastenm{\"u}ller and Christian Gieger and Karsten Suhre and Stefan Karrasch and Annette Peters and Wagner, {Gregory R.} and Michelotti, {Gregory A.} and Mohney, {Robert P.} and Holger Schulz and London, {Stephanie J.}",
year = "2019",
month = "4",
day = "1",
doi = "10.3390/metabo9040061",
language = "English",
volume = "9",
journal = "Metabolites",
issn = "2218-1989",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "4",

}

TY - JOUR

T1 - Metabolomics identifies novel blood biomarkers of pulmonary function and copd in the general population

AU - Yu, Bing

AU - Flexeder, Claudia

AU - McGarrah, Robert W.

AU - Wyss, Annah

AU - Morrison, Alanna C.

AU - North, Kari E.

AU - Boerwinkle, Eric

AU - Kastenmüller, Gabi

AU - Gieger, Christian

AU - Suhre, Karsten

AU - Karrasch, Stefan

AU - Peters, Annette

AU - Wagner, Gregory R.

AU - Michelotti, Gregory A.

AU - Mohney, Robert P.

AU - Schulz, Holger

AU - London, Stephanie J.

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Determination of metabolomic signatures of pulmonary function and chronic obstructive pulmonary disease (COPD) in the general population could aid in identification and understanding of early disease processes. Metabolome measurements were performed on serum from 4742 individuals (2354 African-Americans and 1529 European-Americans from the Atherosclerosis Risk in Communities study and 859 Europeans from the Cooperative Health Research in the Region of Augsburg study). We examined 368 metabolites in relation to cross-sectional measures of forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC), their ratio (FEV1/FVC) and COPD using multivariable regression followed by meta-analysis. At a false discovery rate of 0.05, 95 metabolites were associated with FEV1 and 100 with FVC (73 overlapping), including inverse associations with branched-chain amino acids and positive associations with glutamine. Ten metabolites were associated with FEV1/FVC and seventeen with COPD (393 cases). Enriched pathways of amino acid metabolism were identified. Associations with FEV1 and FVC were not driven by individuals with COPD. We identified novel metabolic signatures of pulmonary function and COPD in African and European ancestry populations. These may allow development of biomarkers in the general population of early disease pathogenesis, before pulmonary function has decreased to levels diagnostic for COPD.

AB - Determination of metabolomic signatures of pulmonary function and chronic obstructive pulmonary disease (COPD) in the general population could aid in identification and understanding of early disease processes. Metabolome measurements were performed on serum from 4742 individuals (2354 African-Americans and 1529 European-Americans from the Atherosclerosis Risk in Communities study and 859 Europeans from the Cooperative Health Research in the Region of Augsburg study). We examined 368 metabolites in relation to cross-sectional measures of forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC), their ratio (FEV1/FVC) and COPD using multivariable regression followed by meta-analysis. At a false discovery rate of 0.05, 95 metabolites were associated with FEV1 and 100 with FVC (73 overlapping), including inverse associations with branched-chain amino acids and positive associations with glutamine. Ten metabolites were associated with FEV1/FVC and seventeen with COPD (393 cases). Enriched pathways of amino acid metabolism were identified. Associations with FEV1 and FVC were not driven by individuals with COPD. We identified novel metabolic signatures of pulmonary function and COPD in African and European ancestry populations. These may allow development of biomarkers in the general population of early disease pathogenesis, before pulmonary function has decreased to levels diagnostic for COPD.

KW - Chronic obstructive pulmonary disease

KW - Forced expiratory volume

KW - Metabolome

KW - Metabolomics

KW - Respiratory function tests

UR - http://www.scopus.com/inward/record.url?scp=85068556014&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068556014&partnerID=8YFLogxK

U2 - 10.3390/metabo9040061

DO - 10.3390/metabo9040061

M3 - Article

VL - 9

JO - Metabolites

JF - Metabolites

SN - 2218-1989

IS - 4

M1 - 61

ER -